Cleared Traditional

K203774 - SmartAdjust technology (FDA 510(k) Clearance)

Jan 2022
Decision
400d
Days
Class 2
Risk

K203774 is an FDA 510(k) clearance for the SmartAdjust technology. This device is classified as a Interoperable Automated Glycemic Controller (Class II - Special Controls, product code QJI).

Submitted by Insulet Corporation (Acton, US). The FDA issued a Cleared decision on January 27, 2022, 400 days after receiving the submission on December 23, 2020.

This device falls under the Chemistry FDA review panel. Regulated under 21 CFR 862.1356. An Interoperable Automated Glycemic Controller Is A Device Intended To Automatically Calculate Drug Doses Based On Inputs Such As Glucose And Other Relevant Physiological Parameters, And To Command The Delivery Of Such Drug Doses From A Connected Infusion Pump. Interoperable Automated Glycemic Controllers Are Designed To Reliably And Securely Communicate With Digitally Connected Devices To Allow Drug Delivery Commands To Be Sent, Received, Executed, And Confirmed. Interoperable Automated Glycemic Controllers Are Intended To Be Used In Conjunction With Digitally Connected Devices For The Purpose Of Maintaining Glycemic Control..

Submission Details

510(k) Number K203774 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 23, 2020
Decision Date January 27, 2022
Days to Decision 400 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF

Device Classification

Product Code QJI — Interoperable Automated Glycemic Controller
Device Class Class II - Special Controls
CFR Regulation 21 CFR 862.1356
Definition An Interoperable Automated Glycemic Controller Is A Device Intended To Automatically Calculate Drug Doses Based On Inputs Such As Glucose And Other Relevant Physiological Parameters, And To Command The Delivery Of Such Drug Doses From A Connected Infusion Pump. Interoperable Automated Glycemic Controllers Are Designed To Reliably And Securely Communicate With Digitally Connected Devices To Allow Drug Delivery Commands To Be Sent, Received, Executed, And Confirmed. Interoperable Automated Glycemic Controllers Are Intended To Be Used In Conjunction With Digitally Connected Devices For The Purpose Of Maintaining Glycemic Control.